[
  {
    "ts": null,
    "headline": "Pfizer hits setback in obesity drug race as GLP-1 trial halts",
    "summary": "Pfizer (PFE) is ending a late-stage trial of its once-daily GLP-1 pill, Danuglipron, after a participant experienced a liver injury. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination Overtime to break down the details, as well as preview what to watch as Johnson & Johnson (JNJ) prepares to report earnings. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.",
    "url": "https://finnhub.io/api/news?id=c67cc2c67c52b69808250a78258a981296f200d791f326373dd7ba603cb1d69c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744667089,
      "headline": "Pfizer hits setback in obesity drug race as GLP-1 trial halts",
      "id": 133917776,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) is ending a late-stage trial of its once-daily GLP-1 pill, Danuglipron, after a participant experienced a liver injury. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination Overtime to break down the details, as well as preview what to watch as Johnson & Johnson (JNJ) prepares to report earnings. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.",
      "url": "https://finnhub.io/api/news?id=c67cc2c67c52b69808250a78258a981296f200d791f326373dd7ba603cb1d69c"
    }
  },
  {
    "ts": null,
    "headline": "Top Analyst Reports for Bank of America, Chevron & Stryker",
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation (BAC), Chevron Corporation (CVX) and Stryker Corporation (SYK), as well as two micro-cap stocks Value Line, Inc. (VALU) and Sypris Solutions, Inc. (SYPR).",
    "url": "https://finnhub.io/api/news?id=b900d70f82e7a836c0670038ac9a30617863fff4af725bf64240e36406847a56",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744665300,
      "headline": "Top Analyst Reports for Bank of America, Chevron & Stryker",
      "id": 133917784,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation (BAC), Chevron Corporation (CVX) and Stryker Corporation (SYK), as well as two micro-cap stocks Value Line, Inc. (VALU) and Sypris Solutions, Inc. (SYPR).",
      "url": "https://finnhub.io/api/news?id=b900d70f82e7a836c0670038ac9a30617863fff4af725bf64240e36406847a56"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Rise Monday Afternoon",
    "summary": "Health care stocks were higher Monday afternoon, with the NYSE Health Care Index rising 0.4% and the",
    "url": "https://finnhub.io/api/news?id=9f2a1731967f9be71c3d8da809f7f4fbce655acc80558f7f511bf725bbbd245f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744654081,
      "headline": "Sector Update: Health Care Stocks Rise Monday Afternoon",
      "id": 133917817,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Health care stocks were higher Monday afternoon, with the NYSE Health Care Index rising 0.4% and the",
      "url": "https://finnhub.io/api/news?id=9f2a1731967f9be71c3d8da809f7f4fbce655acc80558f7f511bf725bbbd245f"
    }
  },
  {
    "ts": null,
    "headline": "Dell stock pops, Pfizer halts GLP-1 pill trial, M&T Bank outlook",
    "summary": "Josh Lipton examines some of the trending stories for investors to watch as part of today's Market Minute. Dell Technologies (DELL) stock pops as investors weigh a temporary tech tariff exemption. Pfizer (PFE) has announced that trials for its weight-loss pill are being halted. M&T Bank's (MTB) first quarter earnings were in line with analyst estimates, though the bank cut its full-year net interest income forecast. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=7473e1aa397de3eaa3a1dd446f79b1ab0aad0289b81d27f0ac16e3cbde31ba4c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744651784,
      "headline": "Dell stock pops, Pfizer halts GLP-1 pill trial, M&T Bank outlook",
      "id": 133908397,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Josh Lipton examines some of the trending stories for investors to watch as part of today's Market Minute. Dell Technologies (DELL) stock pops as investors weigh a temporary tech tariff exemption. Pfizer (PFE) has announced that trials for its weight-loss pill are being halted. M&T Bank's (MTB) first quarter earnings were in line with analyst estimates, though the bank cut its full-year net interest income forecast. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=7473e1aa397de3eaa3a1dd446f79b1ab0aad0289b81d27f0ac16e3cbde31ba4c"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Up on Defensive Demand - Health Care Roundup",
    "summary": "Health-care companies rose sharply as traders rotated into defensive sectors. Kidney-care firm DaVita said its operations were impeded by a recent ransomware attack. Drug giant Pfizer halted...",
    "url": "https://finnhub.io/api/news?id=5dc5df79743c7d080316ddc8e54104469560c3f7002ff7a7dad7a0c389d915dc",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744651528,
      "headline": "Health Care Up on Defensive Demand - Health Care Roundup",
      "id": 133909736,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Health-care companies rose sharply as traders rotated into defensive sectors. Kidney-care firm DaVita said its operations were impeded by a recent ransomware attack. Drug giant Pfizer halted...",
      "url": "https://finnhub.io/api/news?id=5dc5df79743c7d080316ddc8e54104469560c3f7002ff7a7dad7a0c389d915dc"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (NYSE:PFE) Discontinues Danuglipron Development After Safety Review in Study",
    "summary": "Pfizer (NYSE:PFE) recently announced the cessation of Danuglipron's development, an event that coincided with a 3% decline in its share price over the past week. This move was primarily due to safety concerns in clinical studies. Despite achieving key pharmacokinetic goals, the discovery of a potential drug-induced liver injury prompted Pfizer to reassess its strategy. This decision adds weight to the company's stock performance, contrasting with broader market trends, where major indexes...",
    "url": "https://finnhub.io/api/news?id=6ff7fa607c3fb5a23d6c0aaa37a10d160e71eaa74d7caa7f147d23a26b10f18e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744651386,
      "headline": "Pfizer (NYSE:PFE) Discontinues Danuglipron Development After Safety Review in Study",
      "id": 133908398,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (NYSE:PFE) recently announced the cessation of Danuglipron's development, an event that coincided with a 3% decline in its share price over the past week. This move was primarily due to safety concerns in clinical studies. Despite achieving key pharmacokinetic goals, the discovery of a potential drug-induced liver injury prompted Pfizer to reassess its strategy. This decision adds weight to the company's stock performance, contrasting with broader market trends, where major indexes...",
      "url": "https://finnhub.io/api/news?id=6ff7fa607c3fb5a23d6c0aaa37a10d160e71eaa74d7caa7f147d23a26b10f18e"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer to Discontinue Development of Experimental Weight-Loss Pill Danuglipron",
    "summary": "Pfizer (PFE) said Monday it will no longer develop its investigational pill for weight loss after de",
    "url": "https://finnhub.io/api/news?id=24bdb0e725e66f4a04af0538955019843ccf08fcd038c77b2a2fb3eac21b6481",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744651148,
      "headline": "Pfizer to Discontinue Development of Experimental Weight-Loss Pill Danuglipron",
      "id": 133917849,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) said Monday it will no longer develop its investigational pill for weight loss after de",
      "url": "https://finnhub.io/api/news?id=24bdb0e725e66f4a04af0538955019843ccf08fcd038c77b2a2fb3eac21b6481"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE): “Dead Money… Close the Casket,” Says Jim Cramer",
    "summary": "We recently published a list of 10 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks on Jim Cramer’s radar. On Thursday, Mad Money host Jim Cramer cautioned viewers about what may lie ahead once the 90-day pause on new […]",
    "url": "https://finnhub.io/api/news?id=340b8d5ce181f201a5f3938eb9b67e924d2d5b3edb7e74ac84e5388ca53cca60",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744649603,
      "headline": "Pfizer Inc. (PFE): “Dead Money… Close the Casket,” Says Jim Cramer",
      "id": 133908399,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks on Jim Cramer’s radar. On Thursday, Mad Money host Jim Cramer cautioned viewers about what may lie ahead once the 90-day pause on new […]",
      "url": "https://finnhub.io/api/news?id=340b8d5ce181f201a5f3938eb9b67e924d2d5b3edb7e74ac84e5388ca53cca60"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer drops obesity pill development after liver injury report",
    "summary": "Pfizer still has another obesity pill in development, PF-07976016, which is currently in a Phase IIa trial.",
    "url": "https://finnhub.io/api/news?id=978fd76676ef21d1524308953cb02ca06f4f0e16f1fd6ff9db2f543b348c48d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744649102,
      "headline": "Pfizer drops obesity pill development after liver injury report",
      "id": 133908400,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer still has another obesity pill in development, PF-07976016, which is currently in a Phase IIa trial.",
      "url": "https://finnhub.io/api/news?id=978fd76676ef21d1524308953cb02ca06f4f0e16f1fd6ff9db2f543b348c48d3"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Stocks Rally on Tariff Exemption News; Pfizer Discontinues Development of Weight-Loss Drug",
    "summary": "All three major US stock indexes were up in late-morning trading Monday following the announcement o",
    "url": "https://finnhub.io/api/news?id=bb43d3a8ce057a82ae4f43fcebcb16bff665feebcfaadc2f4f174cf48c16b4ac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744645301,
      "headline": "Top Midday Stories: Stocks Rally on Tariff Exemption News; Pfizer Discontinues Development of Weight-Loss Drug",
      "id": 133908056,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "All three major US stock indexes were up in late-morning trading Monday following the announcement o",
      "url": "https://finnhub.io/api/news?id=bb43d3a8ce057a82ae4f43fcebcb16bff665feebcfaadc2f4f174cf48c16b4ac"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's $130B Weight-Loss Dream Just Collapsed",
    "summary": "Pfizer tanks after liver injury kills obesity pill hopes--Lilly, Novo, and Viking surge as investors jump ship",
    "url": "https://finnhub.io/api/news?id=c686d7b6425b6843e9c36d2ea050bb2304d90aa9e7b919888fc32e5f176da52b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744643911,
      "headline": "Pfizer's $130B Weight-Loss Dream Just Collapsed",
      "id": 133908402,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer tanks after liver injury kills obesity pill hopes--Lilly, Novo, and Viking surge as investors jump ship",
      "url": "https://finnhub.io/api/news?id=c686d7b6425b6843e9c36d2ea050bb2304d90aa9e7b919888fc32e5f176da52b"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Halts Obesity-Drug Development. What It Means for Eli Lilly, Novo Nordisk.",
    "summary": "The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.",
    "url": "https://finnhub.io/api/news?id=a43323904b641855f1cc52233aa5d492d6c3e3b97478ff394237763bbfc9d1b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744643700,
      "headline": "Pfizer Halts Obesity-Drug Development. What It Means for Eli Lilly, Novo Nordisk.",
      "id": 133908403,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.",
      "url": "https://finnhub.io/api/news?id=a43323904b641855f1cc52233aa5d492d6c3e3b97478ff394237763bbfc9d1b1"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today",
    "summary": "Pfizer bows, but is not entirely out of the GLP-1 race.",
    "url": "https://finnhub.io/api/news?id=851c58dad62e8dbbdaef0f5e04a8dfcc1947e1558ed2bdb32422f56461152881",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744643550,
      "headline": "Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today",
      "id": 133908184,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer bows, but is not entirely out of the GLP-1 race.",
      "url": "https://finnhub.io/api/news?id=851c58dad62e8dbbdaef0f5e04a8dfcc1947e1558ed2bdb32422f56461152881"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Monday: Apple, Palantir, Intel, Pfizer",
    "summary": "↗️ Goldman Sachs (GS): The Wall Street bank posted better-than-expected results, boosted by a surge in equities trading in the first quarter, which ended just before President Trump's sweeping tariffs disrupted markets.",
    "url": "https://finnhub.io/api/news?id=d063925936e070a53c8d84064e46db0f291eda787cc6f7b43ae5c1df118386d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744642595,
      "headline": "Stocks to Watch Monday: Apple, Palantir, Intel, Pfizer",
      "id": 133908153,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "↗️ Goldman Sachs (GS): The Wall Street bank posted better-than-expected results, boosted by a surge in equities trading in the first quarter, which ended just before President Trump's sweeping tariffs disrupted markets.",
      "url": "https://finnhub.io/api/news?id=d063925936e070a53c8d84064e46db0f291eda787cc6f7b43ae5c1df118386d8"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer just had a big setback in its race for an Ozempic competitor",
    "summary": "Pfizer (PFE) announced Monday that it is ending development of its daily weight-loss pill following a liver injury to a patient participating in a trial.",
    "url": "https://finnhub.io/api/news?id=e6721c36b031d6e8fa68b50530014d04e365b3d68a2b6c88efb58a6fa90be43b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744642553,
      "headline": "Pfizer just had a big setback in its race for an Ozempic competitor",
      "id": 133908186,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) announced Monday that it is ending development of its daily weight-loss pill following a liver injury to a patient participating in a trial.",
      "url": "https://finnhub.io/api/news?id=e6721c36b031d6e8fa68b50530014d04e365b3d68a2b6c88efb58a6fa90be43b"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer, Nvidia, Intel: Stocks in 30",
    "summary": "Brad Smith and Madison Mills take a closer look at some of today's trending tickers. Pfizer (PFE) discontinued its obesity drug after the pill was tied to a potentially drug-induced liver injury. Nvidia (NVDA) says it will make it the first artificial intelligence (AI) supercomputer in the US, marking heavy investment in the US while President Trump imposes hefty tariffs on foreign imports. Intel (INTC) sells its controlling stake in Altera to Silver Lake. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
    "url": "https://finnhub.io/api/news?id=0887485007eb54a5cc254e39224cbf1d67f82a4cfeaafdb31fa5dc4ee1428fa9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744641473,
      "headline": "Pfizer, Nvidia, Intel: Stocks in 30",
      "id": 133908407,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Brad Smith and Madison Mills take a closer look at some of today's trending tickers. Pfizer (PFE) discontinued its obesity drug after the pill was tied to a potentially drug-induced liver injury. Nvidia (NVDA) says it will make it the first artificial intelligence (AI) supercomputer in the US, marking heavy investment in the US while President Trump imposes hefty tariffs on foreign imports. Intel (INTC) sells its controlling stake in Altera to Silver Lake. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
      "url": "https://finnhub.io/api/news?id=0887485007eb54a5cc254e39224cbf1d67f82a4cfeaafdb31fa5dc4ee1428fa9"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Halts Development of Weight-Loss Pill",
    "summary": "Pfizer  is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach for the drug giant.  The company said Monday the stoppage comes after it reviewed clinical data and a study subject developed a liver injury that might have been caused by the drug, called danuglipron.  Halting the drug’s development means  Pfizer  still is unable to get a cut, for now, of the white-hot obesity market, which analysts say could reach $100 billion by the end of the decade.",
    "url": "https://finnhub.io/api/news?id=7eb7c290a43b3bde1f859a6e37d84eebe052f6c0df2e42f1a1b0667722afac88",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744641360,
      "headline": "Pfizer Halts Development of Weight-Loss Pill",
      "id": 133908408,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer  is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach for the drug giant.  The company said Monday the stoppage comes after it reviewed clinical data and a study subject developed a liver injury that might have been caused by the drug, called danuglipron.  Halting the drug’s development means  Pfizer  still is unable to get a cut, for now, of the white-hot obesity market, which analysts say could reach $100 billion by the end of the decade.",
      "url": "https://finnhub.io/api/news?id=7eb7c290a43b3bde1f859a6e37d84eebe052f6c0df2e42f1a1b0667722afac88"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer Inc. (PFE) Among the Best Dividend Paying Stocks According to Hedge Funds?",
    "summary": "We recently published a list of the 11 Best Dividend Paying Stocks According to Hedge Funds. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other best dividend-paying stocks. Dividend-paying stocks have consistently attracted investor interest due to their long-term value. CNBC highlights this by examining the […]",
    "url": "https://finnhub.io/api/news?id=bfbd027a3164272dcfcc32ebcecd2b4f6d44510391f624392477b5cc25d129c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744640475,
      "headline": "Is Pfizer Inc. (PFE) Among the Best Dividend Paying Stocks According to Hedge Funds?",
      "id": 133908409,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently published a list of the 11 Best Dividend Paying Stocks According to Hedge Funds. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other best dividend-paying stocks. Dividend-paying stocks have consistently attracted investor interest due to their long-term value. CNBC highlights this by examining the […]",
      "url": "https://finnhub.io/api/news?id=bfbd027a3164272dcfcc32ebcecd2b4f6d44510391f624392477b5cc25d129c5"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Halts Development of Obesity Drug After Patient Sustains 'Liver Injury'",
    "summary": "Pfizer said it will stop development of an oral weight-loss pill after a participant taking the drug in a clinical trial experienced a \"liver injury.\"",
    "url": "https://finnhub.io/api/news?id=5c8afc69eaf0029ebdd37b6594bc2f1ef0199d4be3dd6b099a64bee3888c56ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744640037,
      "headline": "Pfizer Halts Development of Obesity Drug After Patient Sustains 'Liver Injury'",
      "id": 133908188,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer said it will stop development of an oral weight-loss pill after a participant taking the drug in a clinical trial experienced a \"liver injury.\"",
      "url": "https://finnhub.io/api/news?id=5c8afc69eaf0029ebdd37b6594bc2f1ef0199d4be3dd6b099a64bee3888c56ae"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Abandons Obesity Pill After Trial Liver Injury",
    "summary": "Pfizer Inc. will stop developing an obesity pill after the treatment was linked to a potentially drug-related liver injury in a clinical trial patient. The company won't advance the once-daily medicine into the final stage of testing and will instead invest in earlier-stage treatments for obesity. Damian Garde reports on Bloomberg Television.",
    "url": "https://finnhub.io/api/news?id=da4a23b49175b72d63e31ae5d7a50dd07c4569809c6246814b4e52e88136220d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744639616,
      "headline": "Pfizer Abandons Obesity Pill After Trial Liver Injury",
      "id": 133908411,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. will stop developing an obesity pill after the treatment was linked to a potentially drug-related liver injury in a clinical trial patient. The company won't advance the once-daily medicine into the final stage of testing and will instead invest in earlier-stage treatments for obesity. Damian Garde reports on Bloomberg Television.",
      "url": "https://finnhub.io/api/news?id=da4a23b49175b72d63e31ae5d7a50dd07c4569809c6246814b4e52e88136220d"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer discontinues GLP-1 pill trial, stock trades flat",
    "summary": "Pfizer ends its most advanced clinical trial of an obesity pill to compete in the hot GLP-1 space.",
    "url": "https://finnhub.io/api/news?id=812a7d5093c0afd44509f02ad0687ff7a2a655b8a4d67d85c678a45d2fcf07f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744638810,
      "headline": "Pfizer discontinues GLP-1 pill trial, stock trades flat",
      "id": 133908189,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer ends its most advanced clinical trial of an obesity pill to compete in the hot GLP-1 space.",
      "url": "https://finnhub.io/api/news?id=812a7d5093c0afd44509f02ad0687ff7a2a655b8a4d67d85c678a45d2fcf07f9"
    }
  },
  {
    "ts": null,
    "headline": "Wegovy, Zepbound makers’ stocks rally as a weight-loss-drug competitor drops out",
    "summary": "Wegovy, Zepbound makers’ stocks rally as a weight-loss-drug competitor drops out",
    "url": "https://finnhub.io/api/news?id=4c211fe3a33603657009be603723bb1128bb751a760e4fc8bc372351ff13c347",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744638600,
      "headline": "Wegovy, Zepbound makers’ stocks rally as a weight-loss-drug competitor drops out",
      "id": 133912117,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Wegovy, Zepbound makers’ stocks rally as a weight-loss-drug competitor drops out",
      "url": "https://finnhub.io/api/news?id=4c211fe3a33603657009be603723bb1128bb751a760e4fc8bc372351ff13c347"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer ends development of potential pill obesity treatment",
    "summary": "Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing.  The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a possible drug-induced liver injury that ended once the person stopped taking the treatment.  The once-daily version of the pill was in early-stage testing, with researchers trying to figure out the best dose for patients, a spokeswoman said.",
    "url": "https://finnhub.io/api/news?id=be68b4a616165fd37c1550a41b41641b5388b06b24480445f7efabd8ed2e1acb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744634503,
      "headline": "Pfizer ends development of potential pill obesity treatment",
      "id": 133908413,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing.  The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a possible drug-induced liver injury that ended once the person stopped taking the treatment.  The once-daily version of the pill was in early-stage testing, with researchers trying to figure out the best dose for patients, a spokeswoman said.",
      "url": "https://finnhub.io/api/news?id=be68b4a616165fd37c1550a41b41641b5388b06b24480445f7efabd8ed2e1acb"
    }
  },
  {
    "ts": null,
    "headline": "Safety worries spur Pfizer to drop another obesity pill",
    "summary": "Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it break into the highly lucrative market for obesity drugs.",
    "url": "https://finnhub.io/api/news?id=a0f030e1dfc03d7e4cf8cb1976bc62c871d428d96549351fdac29c943db780e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744632300,
      "headline": "Safety worries spur Pfizer to drop another obesity pill",
      "id": 133908414,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it break into the highly lucrative market for obesity drugs.",
      "url": "https://finnhub.io/api/news?id=a0f030e1dfc03d7e4cf8cb1976bc62c871d428d96549351fdac29c943db780e6"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer pulls plug on weight-loss pill, citing trial concerns",
    "summary": "Investing.com -- Shares of Pfizer Inc (NYSE:PFE) dipped 1.5% as the pharmaceutical giant announced the discontinuation of its drug candidate danuglipron, which was under investigation for chronic weight management.",
    "url": "https://finnhub.io/api/news?id=25dfcf30214915e2718fe9458211c467926c973317fe43ca1d735841c07427f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744629672,
      "headline": "Pfizer pulls plug on weight-loss pill, citing trial concerns",
      "id": 133908415,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Investing.com -- Shares of Pfizer Inc (NYSE:PFE) dipped 1.5% as the pharmaceutical giant announced the discontinuation of its drug candidate danuglipron, which was under investigation for chronic weight management.",
      "url": "https://finnhub.io/api/news?id=25dfcf30214915e2718fe9458211c467926c973317fe43ca1d735841c07427f1"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Lunch: Apple Leads Q1 Global Smartphone Sales",
    "summary": "Wall Street Lunch: Apple Leads Q1 Global Smartphone Sales",
    "url": "https://finnhub.io/api/news?id=893afd38fff1dd905c57c70d824563f21e2e8ddfc8fb17a57aa1abf7a667e62b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744627800,
      "headline": "Wall Street Lunch: Apple Leads Q1 Global Smartphone Sales",
      "id": 133907186,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=893afd38fff1dd905c57c70d824563f21e2e8ddfc8fb17a57aa1abf7a667e62b"
    }
  },
  {
    "ts": null,
    "headline": "Viking Rallies After Pfizer 'Stumble' Highlights The Takeover Candidate — Again",
    "summary": "Viking Therapeutics stock rocketed Monday after Pfizer said it's scrapping development of its daily weight-loss pill.",
    "url": "https://finnhub.io/api/news?id=fe9ca0ab20d7b08bf125543d65fd0fdf263bd5ebc4b5646f5560b21c5d892ef3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744627506,
      "headline": "Viking Rallies After Pfizer 'Stumble' Highlights The Takeover Candidate — Again",
      "id": 133908416,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Viking Therapeutics stock rocketed Monday after Pfizer said it's scrapping development of its daily weight-loss pill.",
      "url": "https://finnhub.io/api/news?id=fe9ca0ab20d7b08bf125543d65fd0fdf263bd5ebc4b5646f5560b21c5d892ef3"
    }
  },
  {
    "ts": null,
    "headline": "Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition",
    "summary": "Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition",
    "url": "https://finnhub.io/api/news?id=3f7294d4d1517918e9a4c887fc4b98f5c253e52d586c4951d103dba25da6944a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744621700,
      "headline": "Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition",
      "id": 133906687,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=3f7294d4d1517918e9a4c887fc4b98f5c253e52d586c4951d103dba25da6944a"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Shares Slip After Company Scraps Weight-Loss Pill",
    "summary": "By Colin Kellaher Pfizer shares moved lower in premarket trading Monday after the drugmaker said it is scrapping its experimental weight-loss pill danuglipron, keeping the company on the...",
    "url": "https://finnhub.io/api/news?id=b5cfacb38fb6a60d77a70e6a2219107c8f51650295f30a70fbbb27a032f4d9f2",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744614611,
      "headline": "Pfizer Shares Slip After Company Scraps Weight-Loss Pill",
      "id": 133905984,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Pfizer shares moved lower in premarket trading Monday after the drugmaker said it is scrapping its experimental weight-loss pill danuglipron, keeping the company on the...",
      "url": "https://finnhub.io/api/news?id=b5cfacb38fb6a60d77a70e6a2219107c8f51650295f30a70fbbb27a032f4d9f2"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron",
    "summary": "Pfizer Inc. today announced the decision to discontinue development of danuglipron , an oral glucagon-like peptide-1 receptor agonist, which was being investigated for chronic weight...",
    "url": "https://finnhub.io/api/news?id=8b66b74551c131bbd6001836b39ce8712ef9836e42495256c48ebbdc654927dd",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744613163,
      "headline": "Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron",
      "id": 133905807,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Pfizer Inc. today announced the decision to discontinue development of danuglipron , an oral glucagon-like peptide-1 receptor agonist, which was being investigated for chronic weight...",
      "url": "https://finnhub.io/api/news?id=8b66b74551c131bbd6001836b39ce8712ef9836e42495256c48ebbdc654927dd"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Scraps Obesity Pill After Potential Drug-Tied Liver Injury",
    "summary": "Pfizer Scraps Obesity Pill After Potential Drug-Tied Liver Injury",
    "url": "https://finnhub.io/api/news?id=3f6a3844ccfd558b46532e8ce0285351886de85d7298450b7fd0e0110e1c93b9",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744613106,
      "headline": "Pfizer Scraps Obesity Pill After Potential Drug-Tied Liver Injury",
      "id": 133914626,
      "image": "",
      "related": "PFE",
      "source": "DowJones",
      "summary": "Pfizer Scraps Obesity Pill After Potential Drug-Tied Liver Injury",
      "url": "https://finnhub.io/api/news?id=3f6a3844ccfd558b46532e8ce0285351886de85d7298450b7fd0e0110e1c93b9"
    }
  }
]